Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.
We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period.
Gavrila
Alina
A
Division of Endocrinology and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Hsu
William
W
Tsiodras
Sotirios
S
Doweiko
John
J
Gautam
Shiva
S
Martin
Lizabeth
L
Moses
Alan C
AC
Karchmer
Adolf W
AW
Mantzoros
Christos S
CS
D019380:Anti-HIV Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D004311:Double-Blind Method; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000188:drug therapy*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D045162:Thiazolidinediones; D011345:Fenofibrate; D000077205:Pioglitazone